Revolution’s First Phase III Daraxonrasib Data Further Boost RAS Specialist’s High Value

Readout Follows Buyout Rumors At Start Of 2026

 
• By Mandy Jackson
  
Holographic Bar Graph of Growth
Revolution's new data made its value rise above its prior high on buyout rumors (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D